A pre-print study by V.B. Larsen et al titled “Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents: A Norwegian Nationwide Register-Based Study” posted on 21 December 2023 reveals what should already be known had any half-decent clinical trial was conducted for the so-called vaccine. The introduction (indirectly) makes that point:
The aim of this nationwide study was to assess short- and mid-term safety of SARS-CoV-2 mRNA vaccines in all adolescents aged 12–19 years in Norway by exploring associations with preselected adverse events.
The paper is 22 pages long. The main text is about 10 pages, the remaining are acknowledgements, references, tables and figures.
The study sample included
…496,432 adolescents born in 2002–2009, residing in Norway (since January 1, 2017, or earlier) and unvaccinated against SARS-CoV-2 when the age-specific vaccination waves started: September 6, 2021 (12–15 years), August 23, 2021 (16–17 years), and April 5, 2021 (18–19 years).
Of these 496,432 individuals, 255,172 (51.4%) are male and 241,260 (48.6%) are female. Most were vaccinated with the Pfizer product. Overall, 181,556 received one dose, 168,698 received two doses, 59,092 received more than two doses, and 87,086 were unvaccinated.
For a given adverse event, four categories are compared to the unvaccinated (control) group: one dose and inside the risk window, one dose and outside the risk window, two doses and inside the risk window, and two doses and outside the risk window.
For some adverse events, there seems to be no significant difference whereas it is notable for others. Typically, problems are reported to occur after the second dose rather than the first dose. For example:
Acute appendicitis (two doses and outside the risk window), aIRR: 1.33; 95% CI: 1.08–1.64.
Anaphylactic reaction (two doses and inside the risk window), aIRR: 10.05; 95% CI: 1.22–82.74.
Epilepsy and convulsions (two doses and inside the risk window), aIRR: 1.49, 95% CI: 0.99–2.26.
Myocarditis and pericarditis (two doses and inside the risk window), aIRR: 5.27; 95% CI: 1.98–14.05.
Lymphadenopathy (two doses and inside the risk window), aIRR: 2.33; 95% CI: 1.46–3.72.
Venous thromboembolic events (two doses and outside the risk window), IRR: 2.55; 95% CI: 0.93–7.02.
Of course, there is still the issue of long-term effects…
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
Comments